Multidisciplinary approach of colorectal cancer liver metastases
|
摘要
Large bowel cancer is a worldwide public health challenge.More than one third of patients present an advanced stage of disease at diagnosis and the liver is the most common site of metastases.Selection criteria for early diagnosis,chemotherapy and surgery have been recently expanded.The definition of resectability remains unclear.The presence of metastases is the most significant prognostic factor.For this reason the surgical resection of hepatic metastases is the leading treatment.The most appropriate resection approach remains to be defined.The two step and simultaneous resection processes of both primary and metastases have comparable survival long-term outcomes.The advent of targeted biological chemotherapeutic agents and the development of loco-regional therapies(chemoembolization,thermal ablation,arterial infusion chemotherapy) contribute to extend favorable results.Standardized evidence-based protocols are missing,hence optimal management of hepatic metastases should be single patient tailored and decided by a multidisciplinary team.This article reviews the outcomes of resection,systemic and loco-regional therapies of liver metastases originating from large bowel cancer.
Large bowel cancer is a worldwide public health challenge.More than one third of patients present an advanced stage of disease at diagnosis and the liver is the most common site of metastases.Selection criteria for early diagnosis,chemotherapy and surgery have been recently expanded.The definition of resectability remains unclear.The presence of metastases is the most significant prognostic factor.For this reason the surgical resection of hepatic metastases is the leading treatment.The most appropriate resection approach remains to be defined.The two step and simultaneous resection processes of both primary and metastases have comparable survival long-term outcomes.The advent of targeted biological chemotherapeutic agents and the development of loco-regional therapies(chemoembolization,thermal ablation,arterial infusion chemotherapy) contribute to extend favorable results.Standardized evidence-based protocols are missing,hence optimal management of hepatic metastases should be single patient tailored and decided by a multidisciplinary team.This article reviews the outcomes of resection,systemic and loco-regional therapies of liver metastases originating from large bowel cancer.
Large bowel cancer is a worldwide public health challenge.More than one third of patients present an advanced stage of disease at diagnosis and the liver is the most common site of metastases.Selection criteria for early diagnosis,chemotherapy and surgery have been recently expanded.The definition of resectability remains unclear.The presence of metastases is the most significant prognostic factor.For this reason the surgical resection of hepatic metastases is the leading treatment.The most appropriate resection approach remains to be defined.The two step and simultaneous resection processes of both primary and metastases have comparable survival long-term outcomes.The advent of targeted biological chemotherapeutic agents and the development of loco-regional therapies(chemoembolization,thermal ablation,arterial infusion chemotherapy) contribute to extend favorable results.Standardized evidence-based protocols are missing,hence optimal management of hepatic metastases should be single patient tailored and decided by a multidisciplinary team.This article reviews the outcomes of resection,systemic and loco-regional therapies of liver metastases originating from large bowel cancer.
引文
1 World Health Organization.International Agency for Research in Cancer.Globocan 2012:estimated cancer incidence,mortality and prevalence worldwide 2012.[accessed 2016 Aug 20].Available from:http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
2 Zhang YL,Zhang ZS,Wu BP,Zhou DY.Early diagnosis for colorectal cancer in China.World J Gastroenterol 2002;8:21-25[PMID:11833064 DOI:10.3748/wjg.v8.i1.21]
3 Renehan AG,Egger M,Saunders MP,O’Dwyer ST.Impact on survival of intensive follow up after curative resection for colorectal cancer:systematic review and meta-analysis of randomised trials.BMJ2002;324:813[PMID:11934773]
4 Simmonds PC,Primrose JN,Colquitt JL,Garden OJ,Poston GJ,Rees M.Surgical resection of hepatic metastases from colorectal cancer:a systematic review of published studies.Br J Cancer 2006;94:982-999[PMID:16538219]
5 Pawlik TM,Schulick RD,Choti MA.Expanding criteria for resectability of colorectal liver metastases.Oncologist 2008;13:51-64[PMID:18245012 DOI:10.1634/theoncologist.2007-0142]
6 Hadden WJ,de Reuver PR,Brown K,Mittal A,Samra JS,Hugh TJ.Resection of colorectal liver metastases and extra-hepatic disease:a systematic review and proportional meta-analysis of survival outcomes.HPB(Oxford)2016;18:209-220[PMID:27017160 DOI:10.1016/j.hpb.2015.12.004]
7 Abdalla EK,Vauthey JN,Ellis LM,Ellis V,Pollock R,Broglio KR,Hess K,Curley SA.Recurrence and outcomes following hepatic resection,radiofrequency ablation,and combined resection/ablation for colorectal liver metastases.Ann Surg 2004;239:818-825;discussion825-827[PMID:15166961]
8 Bismuth H,Adam R,Lévi F,Farabos C,Waechter F,Castaing D,Majno P,Engerran L.Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.Ann Surg 1996;224:509-520;discussion 520-522[PMID:8857855]
9 Nordlinger B,Benoist S.Benefits and risks of neoadjuvant therapy for liver metastases.J Clin Oncol 2006;24:4954-4955[PMID:17075112]
10 Van Cutsem E,Nordlinger B,Adam R,K?hne CH,Pozzo C,Poston G,Ychou M,Rougier P.Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.Eur J Cancer 2006;42:2212-2221[PMID:16904315 DOI:10.1016/j.ejca.2006.04.012]
11 Folprecht G,Gruenberger T,Bechstein WO,Raab HR,Lordick F,Hartmann JT,Lang H,Frilling A,Stoehlmacher J,Weitz J,Konopke R,Stroszczynski C,Liersch T,Ockert D,Herrmann T,Goekkurt E,Parisi F,K?hne CH.Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab:the CELIM randomised phase 2 trial.Lancet Oncol 2010;11:38-47[PMID:19942479 DOI:10.1016/S1470-2045(09)70330-4]
12 Nordlinger B,Van Cutsem E,Rougier P,K?hne CH,Ychou M,Sobrero A,Adam R,Arvidsson D,Carrato A,Georgoulias V,Giuliante F,Glimelius B,Golling M,Gruenberger T,Tabernero J,Wasan H,Poston G.Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer?Areport from the European Colorectal Metastases Treatment Group.Eur J Cancer 2007;43:2037-2045[PMID:17766104 DOI:10.1016/j.ejca.2007.07.017]
13 Van Cutsem E,Nordlinger B,Cervantes A.Advanced colorectal cancer:ESMO Clinical Practice Guidelines for treatment.Ann Oncol2010;21 Suppl 5:v93-v97[PMID:20555112 DOI:10.1093/annonc/mdq222]
14 Isoniemi H,Osterlund P.Surgery combined with oncological treatments in liver metastases from colorectal cancer.Scand J Surg2011;100:35-41[PMID:21482503]
15 Chua TC,Saxena A,Liauw W,Kokandi A,Morris DL.Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases.Ann Surg Oncol 2010;17:492-501[PMID:19856028 DOI:10.1245/s10434-009-0781-1]
16 Schroeder RA,Marroquin CE,Bute BP,Khuri S,Henderson WG,Kuo PC.Predictive indices of morbidity and mortality after liver resection.Ann Surg 2006;243:373-379[PMID:16495703 DOI:10.1097/01.sla.0000201483.95911.08]
17 Dinant S,de Graaf W,Verwer BJ,Bennink RJ,van Lienden KP,Gouma DJ,van Vliet AK,van Gulik TM.Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CTvolumetry.J Nucl Med 2007;48:685-692[PMID:17475954 DOI:10.2967/jnumed.106.038430]
18 Erdogan D,Heijnen BH,Bennink RJ,Kok M,Dinant S,Straatsburg IH,Gouma DJ,van Gulik TM.Preoperative assessment of liver function:a comparison of 99m Tc-Mebrofenin scintigraphy with indocyanine green clearance test.Liver Int 2004;24:117-123[PMID:15078475 DOI:10.1111/j.1478-3231.2004.00901.x]
19 Zorzi D,Laurent A,Pawlik TM,Lauwers GY,Vauthey JN,Abdalla EK.Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.Br J Surg 2007;94:274-286[PMID:17315288 DOI:10.1002/bjs.5719]
20 Fernandez FG,Ritter J,Goodwin JW,Linehan DC,Hawkins WG,Strasberg SM.Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.J Am Coll Surg 2005;200:845-853[PMID:15922194DOI:10.1016/j.jamcollsurg.2005.01.024]
21 Fausto N,Campbell JS,Riehle KJ.Liver regeneration.Hepatology2006;43:S45-S53[PMID:16447274 DOI:10.1002/hep.20969]
22 Ikeda Y,Matsumata T,Takenaka K,Sasaki O,Soejima K,Sugimachi K.Preliminary report of tumor metastasis during liver regeneration after hepatic resection in rats.Eur J Surg Oncol 1995;21:188-190[PMID:7720894 DOI:10.1016/S0748-7983(95)90468-9]
23 Mizutani J,Hiraoka T,Yamashita R,Miyauchi Y.Promotion of hepatic metastases by liver resection in the rat.Br J Cancer 1992;65:794-797[PMID:1616850 DOI:10.1038/bjc.1992.170]
24 Niekel MC,Bipat S,Stoker J.Diagnostic imaging of colorectal liver metastases with CT,MR imaging,FDG PET,and/or FDG PET/CT:a meta-analysis of prospective studies including patients who have not previously undergone treatment.Radiology 2010;257:674-684[PMID:20829538 DOI:10.1148/radiol.10100729]
25 Glover C,Douse P,Kane P,Karani J,Meire H,Mohammadtaghi S,Allen-Mersh TG.Accuracy of investigations for asymptomatic colorectal liver metastases.Dis Colon Rectum 2002;45:476-484[PMID:12006929]
26 Choi DJ,Kwak JM,Kim J,Woo SU,Kim SH.Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer:its role in staging and impact on treatment strategy.J Surg Oncol 2010;102:588-592[PMID:20607759 DOI:10.1002/jso.21651]
27 Lucchese AM,Kalil AN,Schwengber A,Suwa E,Rolim de Moura GG.Usefulness of intraoperative ultrasonography in liver resections due to colon cancer metastasis.Int J Surg 2015;20:140-144[PMID:26118601 DOI:10.1016/j.ijsu.2015.06.053]
28 Mattar RE,Al-Alem F,Simoneau E,Hassanain M.Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection.World J Gastroenterol 2016;22:567-581[PMID:26811608DOI:10.3748/wjg.v22.i2.567]
29 Vauthey JN,Choti MA,Helton WS.AHPBA/SSO/SSAT Consensus Conference on hepatic colorectal metastases:rationale and overview of the conference.January 25,2006.Ann Surg Oncol 2006;13:1259-1260[PMID:16952025 DOI:10.1245/s10434-006-9017-9]
30 Ksienski D,Woods R,Speers C,Kennecke H.Patterns of referral and resection among patients with liver-only metastatic colorectal cancer(MCRC).Ann Surg Oncol 2010;17:3085-3093[PMID:20839067DOI:10.1245/s10434-010-1304-9]
31 House MG,Ito H,G?nen M,Fong Y,Allen PJ,De Matteo RP,Brennan MF,Blumgart LH,Jarnagin WR,D’Angelica MI.Survival after hepatic resection for metastatic colorectal cancer:trends in outcomes for 1,600 patients during two decades at a single institution.J Am Coll Surg 2010;210:744-752,752-755[PMID:20421043]
32 Chua TC,Saxena A,Liauw W,Chu F,Morris DL.Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases--a systematic review.Eur J Cancer 2012;48:1757-1765[PMID:22153217 DOI:10.1016/j.ejca.2011.10.034]
33 Ruiz-Tovar J,López Hervás P.Repeated liver resection for recurrence of colorectal cancer metastases.Clin Transl Oncol 2010;12:634-638[PMID:20851805 DOI:10.1007/s12094-010-0569-6]
34 Fong Y,Fortner J,Sun RL,Brennan MF,Blumgart LH.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases.Ann Surg 1999;230:309-318;discussion 318-321[PMID:10493478 DOI:10.1097/00000658-199909000-00004]
35 Mann CD,Metcalfe MS,Leopardi LN,Maddern GJ.The clinical risk score:emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases.Arch Surg 2004;139:1168-1172[PMID:15545561 DOI:10.1001/archsurg.139.11.1168]
36 Nagashima I,Takada T,Adachi M,Nagawa H,Muto T,Okinaga K.Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection:comparison of our scoring system to the positive number of risk factors.World J Gastroenterol 2006;12:6305-6309[PMID:17072953 DOI:10.3748/wjg.v12.i39.6305]
37 Ferrero A,ViganòL,Polastri R,Muratore A,Eminefendic H,Regge D,Capussotti L.Postoperative liver dysfunction and future remnant liver:where is the limit?Results of a prospective study.World J Surg 2007;31:1643-1651[PMID:17551779]
38 Lykoudis PM,O’Reilly D,Nastos K,Fusai G.Systematic review of surgical management of synchronous colorectal liver metastases.Br JSurg 2014;101:605-612[PMID:24652674 DOI:10.1002/bjs.9449]
39 Waisberg J,Ivankovics IG.Liver-first approach of colorectal cancer with synchronous hepatic metastases:A reverse strategy.World JHepatol 2015;7:1444-1449[PMID:26085905 DOI:10.4254/wjh.v7.i11.1444]
40 Feng Q,Wei Y,Zhu D,Ye L,Lin Q,Li W,Qin X,Lyu M,Xu J.Timing of hepatectomy for resectable synchronous colorectal liver metastases:for whom simultaneous resection is more suitable--a meta-analysis.PLo S One 2014;9:e104348[PMID:25093337 DOI:10.1371/journal.pone.0104348]
41 Ruers TJ,Hagendoorn J.Treatment dilemmas in patients with synchronous colorectal liver metastases.Recent Results Cancer Res2012;196:37-49[PMID:23129365]
42 Bischof DA,Clary BM,Maithel SK,Pawlik TM.Surgical management of disappearing colorectal liver metastases.Br J Surg2013;100:1414-1420[PMID:24037559 DOI:10.1002/bjs.9213]
43 Nordlinger B,Sorbye H,Glimelius B,Poston GJ,Schlag PM,Rougier P,Bechstein WO,Primrose JN,Walpole ET,Finch-Jones M,Jaeck D,Mirza D,Parks RW,Mauer M,Tanis E,Van Cutsem E,Scheithauer W,Gruenberger T.Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer(EORTC 40983):long-term results of a randomised,controlled,phase 3 trial.Lancet Oncol 2013;14:1208-1215[PMID:24120480DOI:10.1016/S1470-2045(13)70447-9]
44 Karoui M,Penna C,Amin-Hashem M,Mitry E,Benoist S,Franc B,Rougier P,Nordlinger B.Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.Ann Surg2006;243:1-7[PMID:16371728]
45 Mitry E,Fields AL,Bleiberg H,Labianca R,Portier G,Tu D,Nitti D,Torri V,Elias D,O’Callaghan C,Langer B,Martignoni G,BouchéO,Lazorthes F,Van Cutsem E,Bedenne L,Moore MJ,Rougier P.Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer:a pooled analysis of two randomized trials.J Clin Oncol 2008;26:4906-4911[PMID:18794541 DOI:10.1200/JCO.2008.17.3781]
46 Power DG,Kemeny NE.Role of adjuvant therapy after resection of colorectal cancer liver metastases.J Clin Oncol 2010;28:2300-2309[PMID:20368552 DOI:10.1200/JCO.2009.26.9340]
47 Brandi G,De Lorenzo S,Nannini M,Curti S,Ottone M,Dall’Olio FG,Barbera MA,Pantaleo MA,Biasco G.Adjuvant chemotherapy for resected colorectal cancer metastases:Literature review and metaanalysis.World J Gastroenterol 2016;22:519-533[PMID:26811604DOI:10.3748/wjg.v22.i2.519]
48 National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology.Colon Cancer(version 2.2016).[accessed2016 Jan 24].Available from:URL:http://www.nccn.org
49 Ychou M,Hohenberger W,Thezenas S,Navarro M,Maurel J,Bokemeyer C,Shacham-Shmueli E,Rivera F,Kwok-Keung Choi C,Santoro A.A randomized phase III study comparing adjuvant5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.Ann Oncol 2009;20:1964-1970[PMID:19567451 DOI:10.1093/annonc/mdp236]
50 Adam R,de Gramont A,Figueras J,Kokudo N,Kunstlinger F,Loyer E,Poston G,Rougier P,Rubbia-Brandt L,Sobrero A,Teh C,Tejpar S,Van Cutsem E,Vauthey JN,P?hlman L.Managing synchronous liver metastases from colorectal cancer:a multidisciplinary international consensus.Cancer Treat Rev 2015;41:729-741[PMID:26417845DOI:10.1016/j.ctrv.2015.06.006]
51 Masi G,Loupakis F,Pollina L,Vasile E,Cupini S,Ricci S,Brunetti IM,Ferraldeschi R,Naso G,Filipponi F,Pietrabissa A,Goletti O,Baldi G,Fornaro L,Andreuccetti M,Falcone A.Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with5-fluorouracil/leucovorin,oxaliplatin,and irinotecan(FOLFOXIRI)followed by radical surgery of metastases.Ann Surg 2009;249:420-425[PMID:19247029 DOI:10.1097/SLA.0b013e31819a0486]
52 Giacchetti S,Itzhaki M,Gruia G,Adam R,Zidani R,Kunstlinger F,Brienza S,Alafaci E,Bertheault-Cvitkovic F,Jasmin C,Reynes M,Bismuth H,Misset JL,Lévi F.Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil,leucovorin,oxaliplatin and surgery.Ann Oncol 1999;10:663-669[PMID:10442188 DOI:10.1023/A:1008347829017]
53 Falcone A,Ricci S,Brunetti I,Pfanner E,Allegrini G,Barbara C,CrinòL,Benedetti G,Evangelista W,Fanchini L,Cortesi E,Picone V,Vitello S,Chiara S,Granetto C,Porcile G,Fioretto L,Orlandini C,Andreuccetti M,Masi G.Phase III trial of infusional fluorouracil,leucovorin,oxaliplatin,and irinotecan(FOLFOXIRI)compared with infusional fluorouracil,leucovorin,and irinotecan(FOLFIRI)as firstline treatment for metastatic colorectal cancer:the Gruppo Oncologico Nord Ovest.J Clin Oncol 2007;25:1670-1676[PMID:17470860DOI:10.1200/JCO.2006.09.0928]
54 Ychou M,Rivoire M,Thezenas S,Quenet F,Delpero JR,Rebischung C,Letoublon C,Guimbaud R,Francois E,Ducreux M,Desseigne F,Fabre JM,Assenat E.A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases.The METHEP trial.Ann Surg Oncol 2013;20:4289-4297[PMID:23955585 DOI:10.1245/s10434-013-3217-x]
55 Loupakis F,Cremolini C,Masi G,Lonardi S,Zagonel V,Salvatore L,Cortesi E,Tomasello G,Ronzoni M,Spadi R,Zaniboni A,Tonini G,Buonadonna A,Amoroso D,Chiara S,Carlomagno C,Boni C,Allegrini G,Boni L,Falcone A.Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.N Engl J Med 2014;371:1609-1618[PMID:25337750 DOI:10.1056/NEJMoa1403108]
56 Kabbinavar FF,Schulz J,Mc Cleod M,Patel T,Hamm JT,Hecht JR,Mass R,Perrou B,Nelson B,Novotny WF.Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer:results of a randomized phase II trial.J Clin Oncol 2005;23:3697-3705[PMID:15738537 DOI:10.1200/JCO.2005.05.112]
57 Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G,Rogers B,Ross R,Kabbinavar F.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med 2004;350:2335-2342[PMID:15175435 DOI:10.1056/NEJMoa032691]
58 Saltz LB,Clarke S,Díaz-Rubio E,Scheithauer W,Figer A,Wong R,Koski S,Lichinitser M,Yang TS,Rivera F,Couture F,Sirzén F,Cassidy J.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study.J Clin Oncol 2008;26:2013-2019[PMID:18421054 DOI:10.1200/JCO.2007.14.9930]
59 Gordon CR,Rojavin Y,Patel M,Zins JE,Grana G,Kann B,Simons R,Atabek U.A review on bevacizumab and surgical wound healing:an important warning to all surgeons.Ann Plast Surg 2009;62:707-709[PMID:19461291 DOI:10.1097/SAP.0b013e3181828141]
60 Tamiya A,Yamazaki K,Boku N,Machida N,Kojima T,Taku K,Yasui H,Fukutomi A,Hironaka S,Onozawa Y.Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer:a retrospective review of 65 Japanese patients.Int J Clin Oncol 2009;14:513-517[PMID:19967487 DOI:10.1007/s10147-009-0911-6]
61 Van Cutsem E,Rivera F,Berry S,Kretzschmar A,Michael M,Di Bartolomeo M,Mazier MA,Canon JL,Georgoulias V,Peeters M,Bridgewater J,Cunningham D.Safety and efficacy of first-line bevacizumab with FOLFOX,XELOX,FOLFIRI and fluoropyrimidines in metastatic colorectal cancer:the BEAT study.Ann Oncol 2009;20:1842-1847[PMID:19406901 DOI:10.1093/annonc/mdp233]
62 Okines A,Puerto OD,Cunningham D,Chau I,Van Cutsem E,Saltz L,Cassidy J.Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.Br J Cancer 2009;101:1033-1038[PMID:19789532 DOI:10.1038/sj.bjc.6605259]
63 Wong R,Cunningham D,Barbachano Y,Saffery C,Valle J,Hickish T,Mudan S,Brown G,Khan A,Wotherspoon A,Strimpakos AS,Thomas J,Compton S,Chua YJ,Chau I.A multicentre study of capecitabine,oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.Ann Oncol 2011;22:2042-2048[PMID:21285134 DOI:10.1093/annonc/mdq714]
64 Martin RC,Scoggins CR,Schreeder M,Rilling WS,Laing CJ,Tatum CM,Kelly LR,Garcia-Monaco RD,Sharma VR,Crocenzi TS,Strasberg SM.Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.Cancer 2015;121:3649-3658[PMID:26149602 DOI:10.1002/cncr.29534]
65 Karagkounis G,Torbenson MS,Daniel HD,Azad NS,Diaz LA,Donehower RC,Hirose K,Ahuja N,Pawlik TM,Choti MA.Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.Cancer 2013;119:4137-4144[PMID:24104864 DOI:10.1002/cncr.28347]
66 Nash GM,Gimbel M,Shia J,Nathanson DR,Ndubuisi MI,Zeng ZS,Kemeny N,Paty PB.KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.Ann Surg Oncol 2010;17:572-578[PMID:19727962 DOI:10.1245/s10434-009-0605-3]
67 Stremitzer S,Stift J,Gruenberger B,Tamandl D,Aschacher T,Wolf B,Wrba F,Gruenberger T.KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.Br J Surg2012;99:1575-1582[PMID:23027075 DOI:10.1002/bjs.8909]
68 Vauthey JN,Zimmitti G,Kopetz SE,Shindoh J,Chen SS,Andreou A,Curley SA,Aloia TA,Maru DM.RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.Ann Surg 2013;258:619-626;discussion 626-627[PMID:24018645]
69 Douillard JY,Oliner KS,Siena S,Tabernero J,Burkes R,Barugel M,Humblet Y,Bodoky G,Cunningham D,Jassem J,Rivera F,Kocákova I,Ruff P,B?asińska-Morawiec M,?makal M,Canon JL,Rother M,Williams R,Rong A,Wiezorek J,Sidhu R,Patterson SD.Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.N Engl J Med 2013;369:1023-1034[PMID:24024839 DOI:10.1056/NEJMoa1305275]
70 Bokemeyer C,Bondarenko I,Makhson A,Hartmann JT,Aparicio J,de Braud F,Donea S,Ludwig H,Schuch G,Stroh C,Loos AH,Zubel A,Koralewski P.Fluorouracil,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J Clin Oncol 2009;27:663-671[PMID:19114683 DOI:10.1200/JCO.2008.20.8397]
71 K?hne CH,Poston G,Folprecht G,Ciardiello F,Ronga P,Beier F,Van Cutsem E.FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer:A retrospective subgroup analysis of the CRYSTAL study.Eur JSurg Oncol 2016;42:1540-1547[PMID:27575968 DOI:10.1016/j.ejso.2016.05.038]
72 Garufi C,Torsello A,Tumolo S,Ettorre GM,Zeuli M,Campanella C,Vennarecci G,Mottolese M,Sperduti I,Cognetti F.Cetuximab plus chronomodulated irinotecan,5-fluorouracil,leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases:POCHERtrial.Br J Cancer 2010;103:1542-1547[PMID:20959822 DOI:10.1038/sj.bjc.6605940]
73 Ye LC,Liu TS,Ren L,Wei Y,Zhu DX,Zai SY,Ye QH,Yu Y,Xu B,Qin XY,Xu J.Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.J Clin Oncol 2013;31:1931-1938[PMID:23569301 DOI:10.1200/JCO.2012.44.8308]
74 Maughan TS,Adams RA,Smith CG,Meade AM,Seymour MT,Wilson RH,Idziaszczyk S,Harris R,Fisher D,Kenny SL,Kay E,Mitchell JK,Madi A,Jasani B,James MD,Bridgewater J,Kennedy MJ,Claes B,Lambrechts D,Kaplan R,Cheadle JP.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:results of the randomised phase 3 MRC COIN trial.Lancet 2011;377:2103-2114[PMID:21641636 DOI:10.1016/S0140-6736(11)60613-2]
75 Tveit KM,Guren T,Glimelius B,Pfeiffer P,Sorbye H,Pyrhonen S,Sigurdsson F,Kure E,Ikdahl T,Skovlund E,Fokstuen T,Hansen F,Hofsli E,Birkemeyer E,Johnsson A,Starkhammar H,Yilmaz MK,Keldsen N,Erdal AB,Dajani O,Dahl O,Christoffersen T.Phase III trial of cetuximab with continuous or intermittent fluorouracil,leucovorin,and oxaliplatin(Nordic FLOX)versus FLOX alone in first-line treatment of metastatic colorectal cancer:the NORDIC-VIIstudy.J Clin Oncol 2012;30:1755-1762[PMID:22473155 DOI:10.1200/JCO.2011.38.0915]
76 K?hne CH,Hofheinz R,Mineur L,Letocha H,Greil R,Thaler J,Fernebro E,Gamelin E,Decosta L,Karthaus M.First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.J Cancer Res Clin Oncol 2012;138:65-72[PMID:21960318 DOI:10.1007/s00432-011-1061-6]
77 Douillard JY,Siena S,Cassidy J,Tabernero J,Burkes R,Barugel M,Humblet Y,Bodoky G,Cunningham D,Jassem J,Rivera F,Kocákova I,Ruff P,B?asińska-Morawiec M,?makal M,Canon JL,Rother M,Oliner KS,Wolf M,Gansert J.Randomized,phase III trial of panitumumab with infusional fluorouracil,leucovorin,and oxaliplatin(FOLFOX4)versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer:the PRIMEstudy.J Clin Oncol 2010;28:4697-4705[PMID:20921465 DOI:10.1200/JCO.2009.27.4860]
78 Peeters M,Tabernero J.Resection Rates and Survival in Patients with Wild-Type KRAS/NRAS Metastatic Colorectal Cancer and Liver Metastases:Data from the PRIME Study.Markers in cancer-ASCO,EORTC and NCI meeting;7-9 Nov 2013;Brussels,Belgium
79 Gruenberger T,Bridgewater J,Chau I,García Alfonso P,Rivoire M,Mudan S,Lasserre S,Hermann F,Waterkamp D,Adam R.Bevacizumab plus m FOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer:the OLIVIA multinational randomised phase II trial.Ann Oncol 2015;26:702-708[PMID:25538173 DOI:10.1093/annonc/mdu580]
80 Adam R,de Haas RJ,Wicherts DA,Aloia TA,Delvart V,Azoulay D,Bismuth H,Castaing D.Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?J Clin Oncol 2008;26:3672-3680[PMID:18669451 DOI:10.1200/JCO.2007.15.7297]
81 Hwang M,Jayakrishnan TT,Green DE,George B,Thomas JP,Groeschl RT,Erickson B,Pappas SG,Gamblin TC,Turaga KK.Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease.Eur J Cancer 2014;50:1747-1757[PMID:24767470 DOI:10.1016/j.ejca.2014.03.277]
82 Mulier S,Mulier P,Ni Y,Miao Y,Dupas B,Marchal G,De Wever I,Michel L.Complications of radiofrequency coagulation of liver tumours.Br J Surg 2002;89:1206-1222[PMID:12296886 DOI:10.1046/j.1365-2168.2002.02168.x]
83 Stang A,Fischbach R,Teichmann W,Bokemeyer C,Braumann D.A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases.Eur J Cancer 2009;45:1748-1756[PMID:19356924 DOI:10.1016/j.ejca.2009.03.012]
84 Mulier S,Ni Y,Jamart J,Ruers T,Marchal G,Michel L.Local recurrence after hepatic radiofrequency coagulation:multivariate meta-analysis and review of contributing factors.Ann Surg 2005;242:158-171[PMID:16041205]
85 Martin RC,Scoggins CR,Mc Masters KM.Safety and efficacy of microwave ablation of hepatic tumors:a prospective review of a 5-year experience.Ann Surg Oncol 2010;17:171-178[PMID:19707829DOI:10.1245/s10434-009-0686-z]
86 Abdalla EK,Bauer TW,Chun YS,D’Angelica M,Kooby DA,Jarnagin WR.Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases:expert consensus statements.HPB(Oxford)2013;15:119-130[PMID:23297723 DOI:10.1111/j.1477-2574.2012.00597.x]
87 Swaminath A,Dawson LA.Emerging role of radiotherapy in the management of liver metastases.Cancer J 2010;16:150-155[PMID:20404612 DOI:10.1097/PPO.0b013e3181d7e8b3]
88 Rule W,Timmerman R,Tong L,Abdulrahman R,Meyer J,Boike T,Schwarz RE,Weatherall P,Chinsoo Cho L.Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases.Ann Surg Oncol 2011;18:1081-1087[PMID:21046264DOI:10.1245/s10434-010-1405-5]
89 Kingham TP,D’Angelica M,Kemeny NE.Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases.J Surg Oncol 2010;102:988-995[PMID:21166003 DOI:10.1002/jso.21753]
90 Allen PJ,Nissan A,Picon AI,Kemeny N,Dudrick P,Ben-Porat L,Espat J,Stojadinovic A,Cohen AM,Fong Y,Paty PB.Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases:an institutional experience of 544 consecutive cases.J Am Coll Surg 2005;201:57-65[PMID:15978444 DOI:10.1016/j.jamcollsurg.2005.03.019]
91 Karanicolas PJ,Metrakos P,Chan K,Asmis T,Chen E,Kingham TP,Kemeny N,Porter G,Fields RC,Pingpank J,Dixon E,Wei A,Cleary S,Zogopoulos G,Dey C,D’Angelica M,Fong Y,Dowden S,Ko YJ.Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases:expert consensus statement.Curr Oncol2014;21:e129-e136[PMID:24523610 DOI:10.3747/co.21.1577]
92 Boige V,Malka D,Elias D,Castaing M,De Baere T,Goere D,Dromain C,Pocard M,Ducreux M.Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.Ann Surg Oncol 2008;15:219-226[PMID:17896145 DOI:10.1245/s10434-007-9581-7]
93 Kemeny NE,Niedzwiecki D,Hollis DR,Lenz HJ,Warren RS,Naughton MJ,Weeks JC,Sigurdson ER,Herndon JE,Zhang C,Mayer RJ.Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer:a randomized trial of efficacy,quality of life,and molecular markers(CALGB 9481).JClin Oncol 2006;24:1395-1403[PMID:16505413 DOI:10.1200/JCO.2005.03.8166]
94 Mocellin S,Pilati P,Lise M,Nitti D.Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer:the end of an era?J Clin Oncol 2007;25:5649-5654[PMID:18065736DOI:10.1200/JCO.2007.12.1764]
95 Fiorentini G,Aliberti C,Tilli M,Mulazzani L,Graziano F,Giordani P,Mambrini A,Montagnani F,Alessandroni P,Catalano V,Coschiera P.Intra-arterial infusion of irinotecan-loaded drug-eluting beads(DEBIRI)versus intravenous therapy(FOLFIRI)for hepatic metastases from colorectal cancer:final results of a phase III study.Anticancer Res 2012;32:1387-1395[PMID:22493375]
96 Aliberti C,Tilli M,Benea G,Fiorentini G.Trans-arterial chemoembolization(TACE)of liver metastases from colorectal cancer using irinotecan-eluting beads:preliminary results.Anticancer Res2006;26:3793-3795[PMID:17094403]
97 Fiorentini G,Aliberti C,Turrisi G,Del Conte A,Rossi S,Benea G,Giovanis P.Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads:results of a phase II clinical study.In Vivo 2007;21:1085-1091[PMID:18210761]
98 Aliberti C,Fiorentini G,Muzzio PC,Pomerri F,Tilli M,Dallara S,Benea G.Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead?,drug-eluting bead loaded with irinotecan:results of a phase II clinical study.Anticancer Res2011;31:4581-4587[PMID:22199334]
99 Narayanan G,Barbery K,Suthar R,Guerrero G,Arora G.Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.Anticancer Res 2013;33:2077-2083[PMID:23645758]
100 Lewis AL,Holden RR.DC Bead embolic drug-eluting bead:clinical application in the locoregional treatment of tumours.Expert Opin Drug Deliv 2011;8:153-169[PMID:21222553 DOI:10.1517/17425247.2011.545388]
101 Fiorentini G,Aliberti C,Mulazzani L,Coschiera P,Catalano V,Rossi D,Giordani P,Ricci S.Chemoembolization in colorectal liver metastases:the rebirth.Anticancer Res 2014;34:575-584[PMID:24510986]
102 Fiorentini G,Aliberti C,Sarti D,Coschiera P,Tilli M,Mulazzani L,Giordani P,Graziano F,Gonzalez AM,Marcos RG,Mugnoz FG,Cantore M,Ricci S,Catalano V,Mambrini A.Locoregional therapy and systemic cetuximab to treat colorectal liver metastases.World J Gastrointest Oncol2015;7:47-54[PMID:26090075 DOI:10.4251/wjgo.v7.i6.47]
103 Aliberti C,Carandina R,Sarti D,Mulazzani L,Catalano V,Felicioli A,Coschiera P,Fiorentini G.Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy.Anticancer Res 2016;36:3515-3521[PMID:27354617]
104 Damm R,Seidensticker R,Ulrich G,Breier L,Steffen IG,Seidensticker M,Garlipp B,Mohnike K,Pech M,Amthauer H,Ricke J.Y90 Radioembolization in chemo-refractory metastastic,liver dominant colorectal cancer patients:outcome assessment applying a predictive scoring system.BMC Cancer 2016;16:509[PMID:27439702 DOI:10.1186/s12885-016-2549-x]
105 Lim L,Gibbs P,Yip D,Shapiro JD,Dowling R,Smith D,Little A,Bailey W,Liechtenstein M.A prospective evaluation of treatment with Selective Internal Radiation Therapy(SIR-spheres)in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.BMC Cancer 2005;5:132[PMID:16225697 DOI:10.1186/1471-2407-5-132]
106 Bester L,Meteling B,Pocock N,Saxena A,Chua TC,Morris DL.Radioembolisation with Yttrium-90 microspheres:an effective treatment modality for unresectable liver metastases.J Med Imaging Radiat Oncol 2013;57:72-80[PMID:23374558 DOI:10.1111/j.1754-9485.2012.02459.x]
107 Cosimelli M,Golfieri R,Cagol PP,Carpanese L,Sciuto R,Maini CL,Mancini R,Sperduti I,Pizzi G,Diodoro MG,Perrone M,Giampalma E,Angelelli B,Fiore F,Lastoria S,Bacchetti S,Gasperini D,Geatti O,Izzo F.Multi-centre phase II clinical trial of yttrium-90resin microspheres alone in unresectable,chemotherapy refractory colorectal liver metastases.Br J Cancer 2010;103:324-331[PMID:20628388 DOI:10.1038/sj.bjc.6605770]
108 Hendlisz A,Van den Eynde M,Peeters M,Maleux G,Lambert B,Vannoote J,De Keukeleire K,Verslype C,Defreyne L,Van Cutsem E,Delatte P,Delaunoit T,Personeni N,Paesmans M,Van Laethem JL,Flamen P.Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.J Clin Oncol 2010;28:3687-3694[PMID:20567019DOI:10.1200/JCO.2010.28.5643]
109 Seidensticker R,Denecke T,Kraus P,Seidensticker M,Mohnike K,Fahlke J,Kettner E,Hildebrandt B,Dudeck O,Pech M,Amthauer H,Ricke J.Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases.Cardiovasc Intervent Radiol 2012;35:1066-1073[PMID:21800231 DOI:10.1007/s00270-011-0234-7]
110 Van Cutsem E,Cervantes A,Adam R,Sobrero A,Van Krieken JH,Aderka D,Aranda Aguilar E,Bardelli A,Benson A,Bodoky G,Ciardiello F,D’Hoore A,Diaz-Rubio E,Douillard JY,Ducreux M,Falcone A,Grothey A,Gruenberger T,Haustermans K,Heinemann V,Hoff P,K?hne CH,Labianca R,Laurent-Puig P,Ma B,Maughan T,Muro K,Normanno N,?sterlund P,Oyen WJ,Papamichael D,Pentheroudakis G,Pfeiffer P,Price TJ,Punt C,Ricke J,Roth A,Salazar R,Scheithauer W,Schmoll HJ,Tabernero J,Ta?eb J,Tejpar S,Wasan H,Yoshino T,Zaanan A,Arnold D.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Ann Oncol 2016;27:1386-1422[PMID:27380959 DOI:10.1093/annonc/mdw235]
111 Lordan JT,Karanjia ND,Quiney N,Fawcett WJ,Worthington TR.A 10-year study of outcome following hepatic resection for colorectal liver metastases-The effect of evaluation in a multidisciplinary team setting.Eur J Surg Oncol 2009;35:302-306[PMID:18328668 DOI:10.1016/j.ejso.2008.01.028]
112 Garden OJ,Rees M,Poston GJ,Mirza D,Saunders M,Ledermann J,Primrose JN,Parks RW.Guidelines for resection of colorectal cancer liver metastases.Gut 2006;55 Suppl 3:iii1-iii8[PMID:16835351DOI:10.1136/gut.2006.098053]
113 Ruiz-Tovar J,López Hervás P.Value of third metastasectomy of colorectal adenocarcinoma.Clin Transl Oncol 2007;9:56-58[PMID:17272232 DOI:10.1007/s12094-007-0011-x]
2 Zhang YL,Zhang ZS,Wu BP,Zhou DY.Early diagnosis for colorectal cancer in China.World J Gastroenterol 2002;8:21-25[PMID:11833064 DOI:10.3748/wjg.v8.i1.21]
3 Renehan AG,Egger M,Saunders MP,O’Dwyer ST.Impact on survival of intensive follow up after curative resection for colorectal cancer:systematic review and meta-analysis of randomised trials.BMJ2002;324:813[PMID:11934773]
4 Simmonds PC,Primrose JN,Colquitt JL,Garden OJ,Poston GJ,Rees M.Surgical resection of hepatic metastases from colorectal cancer:a systematic review of published studies.Br J Cancer 2006;94:982-999[PMID:16538219]
5 Pawlik TM,Schulick RD,Choti MA.Expanding criteria for resectability of colorectal liver metastases.Oncologist 2008;13:51-64[PMID:18245012 DOI:10.1634/theoncologist.2007-0142]
6 Hadden WJ,de Reuver PR,Brown K,Mittal A,Samra JS,Hugh TJ.Resection of colorectal liver metastases and extra-hepatic disease:a systematic review and proportional meta-analysis of survival outcomes.HPB(Oxford)2016;18:209-220[PMID:27017160 DOI:10.1016/j.hpb.2015.12.004]
7 Abdalla EK,Vauthey JN,Ellis LM,Ellis V,Pollock R,Broglio KR,Hess K,Curley SA.Recurrence and outcomes following hepatic resection,radiofrequency ablation,and combined resection/ablation for colorectal liver metastases.Ann Surg 2004;239:818-825;discussion825-827[PMID:15166961]
8 Bismuth H,Adam R,Lévi F,Farabos C,Waechter F,Castaing D,Majno P,Engerran L.Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.Ann Surg 1996;224:509-520;discussion 520-522[PMID:8857855]
9 Nordlinger B,Benoist S.Benefits and risks of neoadjuvant therapy for liver metastases.J Clin Oncol 2006;24:4954-4955[PMID:17075112]
10 Van Cutsem E,Nordlinger B,Adam R,K?hne CH,Pozzo C,Poston G,Ychou M,Rougier P.Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.Eur J Cancer 2006;42:2212-2221[PMID:16904315 DOI:10.1016/j.ejca.2006.04.012]
11 Folprecht G,Gruenberger T,Bechstein WO,Raab HR,Lordick F,Hartmann JT,Lang H,Frilling A,Stoehlmacher J,Weitz J,Konopke R,Stroszczynski C,Liersch T,Ockert D,Herrmann T,Goekkurt E,Parisi F,K?hne CH.Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab:the CELIM randomised phase 2 trial.Lancet Oncol 2010;11:38-47[PMID:19942479 DOI:10.1016/S1470-2045(09)70330-4]
12 Nordlinger B,Van Cutsem E,Rougier P,K?hne CH,Ychou M,Sobrero A,Adam R,Arvidsson D,Carrato A,Georgoulias V,Giuliante F,Glimelius B,Golling M,Gruenberger T,Tabernero J,Wasan H,Poston G.Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer?Areport from the European Colorectal Metastases Treatment Group.Eur J Cancer 2007;43:2037-2045[PMID:17766104 DOI:10.1016/j.ejca.2007.07.017]
13 Van Cutsem E,Nordlinger B,Cervantes A.Advanced colorectal cancer:ESMO Clinical Practice Guidelines for treatment.Ann Oncol2010;21 Suppl 5:v93-v97[PMID:20555112 DOI:10.1093/annonc/mdq222]
14 Isoniemi H,Osterlund P.Surgery combined with oncological treatments in liver metastases from colorectal cancer.Scand J Surg2011;100:35-41[PMID:21482503]
15 Chua TC,Saxena A,Liauw W,Kokandi A,Morris DL.Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases.Ann Surg Oncol 2010;17:492-501[PMID:19856028 DOI:10.1245/s10434-009-0781-1]
16 Schroeder RA,Marroquin CE,Bute BP,Khuri S,Henderson WG,Kuo PC.Predictive indices of morbidity and mortality after liver resection.Ann Surg 2006;243:373-379[PMID:16495703 DOI:10.1097/01.sla.0000201483.95911.08]
17 Dinant S,de Graaf W,Verwer BJ,Bennink RJ,van Lienden KP,Gouma DJ,van Vliet AK,van Gulik TM.Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CTvolumetry.J Nucl Med 2007;48:685-692[PMID:17475954 DOI:10.2967/jnumed.106.038430]
18 Erdogan D,Heijnen BH,Bennink RJ,Kok M,Dinant S,Straatsburg IH,Gouma DJ,van Gulik TM.Preoperative assessment of liver function:a comparison of 99m Tc-Mebrofenin scintigraphy with indocyanine green clearance test.Liver Int 2004;24:117-123[PMID:15078475 DOI:10.1111/j.1478-3231.2004.00901.x]
19 Zorzi D,Laurent A,Pawlik TM,Lauwers GY,Vauthey JN,Abdalla EK.Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.Br J Surg 2007;94:274-286[PMID:17315288 DOI:10.1002/bjs.5719]
20 Fernandez FG,Ritter J,Goodwin JW,Linehan DC,Hawkins WG,Strasberg SM.Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.J Am Coll Surg 2005;200:845-853[PMID:15922194DOI:10.1016/j.jamcollsurg.2005.01.024]
21 Fausto N,Campbell JS,Riehle KJ.Liver regeneration.Hepatology2006;43:S45-S53[PMID:16447274 DOI:10.1002/hep.20969]
22 Ikeda Y,Matsumata T,Takenaka K,Sasaki O,Soejima K,Sugimachi K.Preliminary report of tumor metastasis during liver regeneration after hepatic resection in rats.Eur J Surg Oncol 1995;21:188-190[PMID:7720894 DOI:10.1016/S0748-7983(95)90468-9]
23 Mizutani J,Hiraoka T,Yamashita R,Miyauchi Y.Promotion of hepatic metastases by liver resection in the rat.Br J Cancer 1992;65:794-797[PMID:1616850 DOI:10.1038/bjc.1992.170]
24 Niekel MC,Bipat S,Stoker J.Diagnostic imaging of colorectal liver metastases with CT,MR imaging,FDG PET,and/or FDG PET/CT:a meta-analysis of prospective studies including patients who have not previously undergone treatment.Radiology 2010;257:674-684[PMID:20829538 DOI:10.1148/radiol.10100729]
25 Glover C,Douse P,Kane P,Karani J,Meire H,Mohammadtaghi S,Allen-Mersh TG.Accuracy of investigations for asymptomatic colorectal liver metastases.Dis Colon Rectum 2002;45:476-484[PMID:12006929]
26 Choi DJ,Kwak JM,Kim J,Woo SU,Kim SH.Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer:its role in staging and impact on treatment strategy.J Surg Oncol 2010;102:588-592[PMID:20607759 DOI:10.1002/jso.21651]
27 Lucchese AM,Kalil AN,Schwengber A,Suwa E,Rolim de Moura GG.Usefulness of intraoperative ultrasonography in liver resections due to colon cancer metastasis.Int J Surg 2015;20:140-144[PMID:26118601 DOI:10.1016/j.ijsu.2015.06.053]
28 Mattar RE,Al-Alem F,Simoneau E,Hassanain M.Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection.World J Gastroenterol 2016;22:567-581[PMID:26811608DOI:10.3748/wjg.v22.i2.567]
29 Vauthey JN,Choti MA,Helton WS.AHPBA/SSO/SSAT Consensus Conference on hepatic colorectal metastases:rationale and overview of the conference.January 25,2006.Ann Surg Oncol 2006;13:1259-1260[PMID:16952025 DOI:10.1245/s10434-006-9017-9]
30 Ksienski D,Woods R,Speers C,Kennecke H.Patterns of referral and resection among patients with liver-only metastatic colorectal cancer(MCRC).Ann Surg Oncol 2010;17:3085-3093[PMID:20839067DOI:10.1245/s10434-010-1304-9]
31 House MG,Ito H,G?nen M,Fong Y,Allen PJ,De Matteo RP,Brennan MF,Blumgart LH,Jarnagin WR,D’Angelica MI.Survival after hepatic resection for metastatic colorectal cancer:trends in outcomes for 1,600 patients during two decades at a single institution.J Am Coll Surg 2010;210:744-752,752-755[PMID:20421043]
32 Chua TC,Saxena A,Liauw W,Chu F,Morris DL.Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases--a systematic review.Eur J Cancer 2012;48:1757-1765[PMID:22153217 DOI:10.1016/j.ejca.2011.10.034]
33 Ruiz-Tovar J,López Hervás P.Repeated liver resection for recurrence of colorectal cancer metastases.Clin Transl Oncol 2010;12:634-638[PMID:20851805 DOI:10.1007/s12094-010-0569-6]
34 Fong Y,Fortner J,Sun RL,Brennan MF,Blumgart LH.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases.Ann Surg 1999;230:309-318;discussion 318-321[PMID:10493478 DOI:10.1097/00000658-199909000-00004]
35 Mann CD,Metcalfe MS,Leopardi LN,Maddern GJ.The clinical risk score:emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases.Arch Surg 2004;139:1168-1172[PMID:15545561 DOI:10.1001/archsurg.139.11.1168]
36 Nagashima I,Takada T,Adachi M,Nagawa H,Muto T,Okinaga K.Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection:comparison of our scoring system to the positive number of risk factors.World J Gastroenterol 2006;12:6305-6309[PMID:17072953 DOI:10.3748/wjg.v12.i39.6305]
37 Ferrero A,ViganòL,Polastri R,Muratore A,Eminefendic H,Regge D,Capussotti L.Postoperative liver dysfunction and future remnant liver:where is the limit?Results of a prospective study.World J Surg 2007;31:1643-1651[PMID:17551779]
38 Lykoudis PM,O’Reilly D,Nastos K,Fusai G.Systematic review of surgical management of synchronous colorectal liver metastases.Br JSurg 2014;101:605-612[PMID:24652674 DOI:10.1002/bjs.9449]
39 Waisberg J,Ivankovics IG.Liver-first approach of colorectal cancer with synchronous hepatic metastases:A reverse strategy.World JHepatol 2015;7:1444-1449[PMID:26085905 DOI:10.4254/wjh.v7.i11.1444]
40 Feng Q,Wei Y,Zhu D,Ye L,Lin Q,Li W,Qin X,Lyu M,Xu J.Timing of hepatectomy for resectable synchronous colorectal liver metastases:for whom simultaneous resection is more suitable--a meta-analysis.PLo S One 2014;9:e104348[PMID:25093337 DOI:10.1371/journal.pone.0104348]
41 Ruers TJ,Hagendoorn J.Treatment dilemmas in patients with synchronous colorectal liver metastases.Recent Results Cancer Res2012;196:37-49[PMID:23129365]
42 Bischof DA,Clary BM,Maithel SK,Pawlik TM.Surgical management of disappearing colorectal liver metastases.Br J Surg2013;100:1414-1420[PMID:24037559 DOI:10.1002/bjs.9213]
43 Nordlinger B,Sorbye H,Glimelius B,Poston GJ,Schlag PM,Rougier P,Bechstein WO,Primrose JN,Walpole ET,Finch-Jones M,Jaeck D,Mirza D,Parks RW,Mauer M,Tanis E,Van Cutsem E,Scheithauer W,Gruenberger T.Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer(EORTC 40983):long-term results of a randomised,controlled,phase 3 trial.Lancet Oncol 2013;14:1208-1215[PMID:24120480DOI:10.1016/S1470-2045(13)70447-9]
44 Karoui M,Penna C,Amin-Hashem M,Mitry E,Benoist S,Franc B,Rougier P,Nordlinger B.Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.Ann Surg2006;243:1-7[PMID:16371728]
45 Mitry E,Fields AL,Bleiberg H,Labianca R,Portier G,Tu D,Nitti D,Torri V,Elias D,O’Callaghan C,Langer B,Martignoni G,BouchéO,Lazorthes F,Van Cutsem E,Bedenne L,Moore MJ,Rougier P.Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer:a pooled analysis of two randomized trials.J Clin Oncol 2008;26:4906-4911[PMID:18794541 DOI:10.1200/JCO.2008.17.3781]
46 Power DG,Kemeny NE.Role of adjuvant therapy after resection of colorectal cancer liver metastases.J Clin Oncol 2010;28:2300-2309[PMID:20368552 DOI:10.1200/JCO.2009.26.9340]
47 Brandi G,De Lorenzo S,Nannini M,Curti S,Ottone M,Dall’Olio FG,Barbera MA,Pantaleo MA,Biasco G.Adjuvant chemotherapy for resected colorectal cancer metastases:Literature review and metaanalysis.World J Gastroenterol 2016;22:519-533[PMID:26811604DOI:10.3748/wjg.v22.i2.519]
48 National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology.Colon Cancer(version 2.2016).[accessed2016 Jan 24].Available from:URL:http://www.nccn.org
49 Ychou M,Hohenberger W,Thezenas S,Navarro M,Maurel J,Bokemeyer C,Shacham-Shmueli E,Rivera F,Kwok-Keung Choi C,Santoro A.A randomized phase III study comparing adjuvant5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.Ann Oncol 2009;20:1964-1970[PMID:19567451 DOI:10.1093/annonc/mdp236]
50 Adam R,de Gramont A,Figueras J,Kokudo N,Kunstlinger F,Loyer E,Poston G,Rougier P,Rubbia-Brandt L,Sobrero A,Teh C,Tejpar S,Van Cutsem E,Vauthey JN,P?hlman L.Managing synchronous liver metastases from colorectal cancer:a multidisciplinary international consensus.Cancer Treat Rev 2015;41:729-741[PMID:26417845DOI:10.1016/j.ctrv.2015.06.006]
51 Masi G,Loupakis F,Pollina L,Vasile E,Cupini S,Ricci S,Brunetti IM,Ferraldeschi R,Naso G,Filipponi F,Pietrabissa A,Goletti O,Baldi G,Fornaro L,Andreuccetti M,Falcone A.Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with5-fluorouracil/leucovorin,oxaliplatin,and irinotecan(FOLFOXIRI)followed by radical surgery of metastases.Ann Surg 2009;249:420-425[PMID:19247029 DOI:10.1097/SLA.0b013e31819a0486]
52 Giacchetti S,Itzhaki M,Gruia G,Adam R,Zidani R,Kunstlinger F,Brienza S,Alafaci E,Bertheault-Cvitkovic F,Jasmin C,Reynes M,Bismuth H,Misset JL,Lévi F.Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil,leucovorin,oxaliplatin and surgery.Ann Oncol 1999;10:663-669[PMID:10442188 DOI:10.1023/A:1008347829017]
53 Falcone A,Ricci S,Brunetti I,Pfanner E,Allegrini G,Barbara C,CrinòL,Benedetti G,Evangelista W,Fanchini L,Cortesi E,Picone V,Vitello S,Chiara S,Granetto C,Porcile G,Fioretto L,Orlandini C,Andreuccetti M,Masi G.Phase III trial of infusional fluorouracil,leucovorin,oxaliplatin,and irinotecan(FOLFOXIRI)compared with infusional fluorouracil,leucovorin,and irinotecan(FOLFIRI)as firstline treatment for metastatic colorectal cancer:the Gruppo Oncologico Nord Ovest.J Clin Oncol 2007;25:1670-1676[PMID:17470860DOI:10.1200/JCO.2006.09.0928]
54 Ychou M,Rivoire M,Thezenas S,Quenet F,Delpero JR,Rebischung C,Letoublon C,Guimbaud R,Francois E,Ducreux M,Desseigne F,Fabre JM,Assenat E.A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases.The METHEP trial.Ann Surg Oncol 2013;20:4289-4297[PMID:23955585 DOI:10.1245/s10434-013-3217-x]
55 Loupakis F,Cremolini C,Masi G,Lonardi S,Zagonel V,Salvatore L,Cortesi E,Tomasello G,Ronzoni M,Spadi R,Zaniboni A,Tonini G,Buonadonna A,Amoroso D,Chiara S,Carlomagno C,Boni C,Allegrini G,Boni L,Falcone A.Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.N Engl J Med 2014;371:1609-1618[PMID:25337750 DOI:10.1056/NEJMoa1403108]
56 Kabbinavar FF,Schulz J,Mc Cleod M,Patel T,Hamm JT,Hecht JR,Mass R,Perrou B,Nelson B,Novotny WF.Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer:results of a randomized phase II trial.J Clin Oncol 2005;23:3697-3705[PMID:15738537 DOI:10.1200/JCO.2005.05.112]
57 Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G,Rogers B,Ross R,Kabbinavar F.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med 2004;350:2335-2342[PMID:15175435 DOI:10.1056/NEJMoa032691]
58 Saltz LB,Clarke S,Díaz-Rubio E,Scheithauer W,Figer A,Wong R,Koski S,Lichinitser M,Yang TS,Rivera F,Couture F,Sirzén F,Cassidy J.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study.J Clin Oncol 2008;26:2013-2019[PMID:18421054 DOI:10.1200/JCO.2007.14.9930]
59 Gordon CR,Rojavin Y,Patel M,Zins JE,Grana G,Kann B,Simons R,Atabek U.A review on bevacizumab and surgical wound healing:an important warning to all surgeons.Ann Plast Surg 2009;62:707-709[PMID:19461291 DOI:10.1097/SAP.0b013e3181828141]
60 Tamiya A,Yamazaki K,Boku N,Machida N,Kojima T,Taku K,Yasui H,Fukutomi A,Hironaka S,Onozawa Y.Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer:a retrospective review of 65 Japanese patients.Int J Clin Oncol 2009;14:513-517[PMID:19967487 DOI:10.1007/s10147-009-0911-6]
61 Van Cutsem E,Rivera F,Berry S,Kretzschmar A,Michael M,Di Bartolomeo M,Mazier MA,Canon JL,Georgoulias V,Peeters M,Bridgewater J,Cunningham D.Safety and efficacy of first-line bevacizumab with FOLFOX,XELOX,FOLFIRI and fluoropyrimidines in metastatic colorectal cancer:the BEAT study.Ann Oncol 2009;20:1842-1847[PMID:19406901 DOI:10.1093/annonc/mdp233]
62 Okines A,Puerto OD,Cunningham D,Chau I,Van Cutsem E,Saltz L,Cassidy J.Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.Br J Cancer 2009;101:1033-1038[PMID:19789532 DOI:10.1038/sj.bjc.6605259]
63 Wong R,Cunningham D,Barbachano Y,Saffery C,Valle J,Hickish T,Mudan S,Brown G,Khan A,Wotherspoon A,Strimpakos AS,Thomas J,Compton S,Chua YJ,Chau I.A multicentre study of capecitabine,oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.Ann Oncol 2011;22:2042-2048[PMID:21285134 DOI:10.1093/annonc/mdq714]
64 Martin RC,Scoggins CR,Schreeder M,Rilling WS,Laing CJ,Tatum CM,Kelly LR,Garcia-Monaco RD,Sharma VR,Crocenzi TS,Strasberg SM.Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.Cancer 2015;121:3649-3658[PMID:26149602 DOI:10.1002/cncr.29534]
65 Karagkounis G,Torbenson MS,Daniel HD,Azad NS,Diaz LA,Donehower RC,Hirose K,Ahuja N,Pawlik TM,Choti MA.Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.Cancer 2013;119:4137-4144[PMID:24104864 DOI:10.1002/cncr.28347]
66 Nash GM,Gimbel M,Shia J,Nathanson DR,Ndubuisi MI,Zeng ZS,Kemeny N,Paty PB.KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.Ann Surg Oncol 2010;17:572-578[PMID:19727962 DOI:10.1245/s10434-009-0605-3]
67 Stremitzer S,Stift J,Gruenberger B,Tamandl D,Aschacher T,Wolf B,Wrba F,Gruenberger T.KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.Br J Surg2012;99:1575-1582[PMID:23027075 DOI:10.1002/bjs.8909]
68 Vauthey JN,Zimmitti G,Kopetz SE,Shindoh J,Chen SS,Andreou A,Curley SA,Aloia TA,Maru DM.RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.Ann Surg 2013;258:619-626;discussion 626-627[PMID:24018645]
69 Douillard JY,Oliner KS,Siena S,Tabernero J,Burkes R,Barugel M,Humblet Y,Bodoky G,Cunningham D,Jassem J,Rivera F,Kocákova I,Ruff P,B?asińska-Morawiec M,?makal M,Canon JL,Rother M,Williams R,Rong A,Wiezorek J,Sidhu R,Patterson SD.Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.N Engl J Med 2013;369:1023-1034[PMID:24024839 DOI:10.1056/NEJMoa1305275]
70 Bokemeyer C,Bondarenko I,Makhson A,Hartmann JT,Aparicio J,de Braud F,Donea S,Ludwig H,Schuch G,Stroh C,Loos AH,Zubel A,Koralewski P.Fluorouracil,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J Clin Oncol 2009;27:663-671[PMID:19114683 DOI:10.1200/JCO.2008.20.8397]
71 K?hne CH,Poston G,Folprecht G,Ciardiello F,Ronga P,Beier F,Van Cutsem E.FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer:A retrospective subgroup analysis of the CRYSTAL study.Eur JSurg Oncol 2016;42:1540-1547[PMID:27575968 DOI:10.1016/j.ejso.2016.05.038]
72 Garufi C,Torsello A,Tumolo S,Ettorre GM,Zeuli M,Campanella C,Vennarecci G,Mottolese M,Sperduti I,Cognetti F.Cetuximab plus chronomodulated irinotecan,5-fluorouracil,leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases:POCHERtrial.Br J Cancer 2010;103:1542-1547[PMID:20959822 DOI:10.1038/sj.bjc.6605940]
73 Ye LC,Liu TS,Ren L,Wei Y,Zhu DX,Zai SY,Ye QH,Yu Y,Xu B,Qin XY,Xu J.Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.J Clin Oncol 2013;31:1931-1938[PMID:23569301 DOI:10.1200/JCO.2012.44.8308]
74 Maughan TS,Adams RA,Smith CG,Meade AM,Seymour MT,Wilson RH,Idziaszczyk S,Harris R,Fisher D,Kenny SL,Kay E,Mitchell JK,Madi A,Jasani B,James MD,Bridgewater J,Kennedy MJ,Claes B,Lambrechts D,Kaplan R,Cheadle JP.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:results of the randomised phase 3 MRC COIN trial.Lancet 2011;377:2103-2114[PMID:21641636 DOI:10.1016/S0140-6736(11)60613-2]
75 Tveit KM,Guren T,Glimelius B,Pfeiffer P,Sorbye H,Pyrhonen S,Sigurdsson F,Kure E,Ikdahl T,Skovlund E,Fokstuen T,Hansen F,Hofsli E,Birkemeyer E,Johnsson A,Starkhammar H,Yilmaz MK,Keldsen N,Erdal AB,Dajani O,Dahl O,Christoffersen T.Phase III trial of cetuximab with continuous or intermittent fluorouracil,leucovorin,and oxaliplatin(Nordic FLOX)versus FLOX alone in first-line treatment of metastatic colorectal cancer:the NORDIC-VIIstudy.J Clin Oncol 2012;30:1755-1762[PMID:22473155 DOI:10.1200/JCO.2011.38.0915]
76 K?hne CH,Hofheinz R,Mineur L,Letocha H,Greil R,Thaler J,Fernebro E,Gamelin E,Decosta L,Karthaus M.First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.J Cancer Res Clin Oncol 2012;138:65-72[PMID:21960318 DOI:10.1007/s00432-011-1061-6]
77 Douillard JY,Siena S,Cassidy J,Tabernero J,Burkes R,Barugel M,Humblet Y,Bodoky G,Cunningham D,Jassem J,Rivera F,Kocákova I,Ruff P,B?asińska-Morawiec M,?makal M,Canon JL,Rother M,Oliner KS,Wolf M,Gansert J.Randomized,phase III trial of panitumumab with infusional fluorouracil,leucovorin,and oxaliplatin(FOLFOX4)versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer:the PRIMEstudy.J Clin Oncol 2010;28:4697-4705[PMID:20921465 DOI:10.1200/JCO.2009.27.4860]
78 Peeters M,Tabernero J.Resection Rates and Survival in Patients with Wild-Type KRAS/NRAS Metastatic Colorectal Cancer and Liver Metastases:Data from the PRIME Study.Markers in cancer-ASCO,EORTC and NCI meeting;7-9 Nov 2013;Brussels,Belgium
79 Gruenberger T,Bridgewater J,Chau I,García Alfonso P,Rivoire M,Mudan S,Lasserre S,Hermann F,Waterkamp D,Adam R.Bevacizumab plus m FOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer:the OLIVIA multinational randomised phase II trial.Ann Oncol 2015;26:702-708[PMID:25538173 DOI:10.1093/annonc/mdu580]
80 Adam R,de Haas RJ,Wicherts DA,Aloia TA,Delvart V,Azoulay D,Bismuth H,Castaing D.Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?J Clin Oncol 2008;26:3672-3680[PMID:18669451 DOI:10.1200/JCO.2007.15.7297]
81 Hwang M,Jayakrishnan TT,Green DE,George B,Thomas JP,Groeschl RT,Erickson B,Pappas SG,Gamblin TC,Turaga KK.Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease.Eur J Cancer 2014;50:1747-1757[PMID:24767470 DOI:10.1016/j.ejca.2014.03.277]
82 Mulier S,Mulier P,Ni Y,Miao Y,Dupas B,Marchal G,De Wever I,Michel L.Complications of radiofrequency coagulation of liver tumours.Br J Surg 2002;89:1206-1222[PMID:12296886 DOI:10.1046/j.1365-2168.2002.02168.x]
83 Stang A,Fischbach R,Teichmann W,Bokemeyer C,Braumann D.A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases.Eur J Cancer 2009;45:1748-1756[PMID:19356924 DOI:10.1016/j.ejca.2009.03.012]
84 Mulier S,Ni Y,Jamart J,Ruers T,Marchal G,Michel L.Local recurrence after hepatic radiofrequency coagulation:multivariate meta-analysis and review of contributing factors.Ann Surg 2005;242:158-171[PMID:16041205]
85 Martin RC,Scoggins CR,Mc Masters KM.Safety and efficacy of microwave ablation of hepatic tumors:a prospective review of a 5-year experience.Ann Surg Oncol 2010;17:171-178[PMID:19707829DOI:10.1245/s10434-009-0686-z]
86 Abdalla EK,Bauer TW,Chun YS,D’Angelica M,Kooby DA,Jarnagin WR.Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases:expert consensus statements.HPB(Oxford)2013;15:119-130[PMID:23297723 DOI:10.1111/j.1477-2574.2012.00597.x]
87 Swaminath A,Dawson LA.Emerging role of radiotherapy in the management of liver metastases.Cancer J 2010;16:150-155[PMID:20404612 DOI:10.1097/PPO.0b013e3181d7e8b3]
88 Rule W,Timmerman R,Tong L,Abdulrahman R,Meyer J,Boike T,Schwarz RE,Weatherall P,Chinsoo Cho L.Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases.Ann Surg Oncol 2011;18:1081-1087[PMID:21046264DOI:10.1245/s10434-010-1405-5]
89 Kingham TP,D’Angelica M,Kemeny NE.Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases.J Surg Oncol 2010;102:988-995[PMID:21166003 DOI:10.1002/jso.21753]
90 Allen PJ,Nissan A,Picon AI,Kemeny N,Dudrick P,Ben-Porat L,Espat J,Stojadinovic A,Cohen AM,Fong Y,Paty PB.Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases:an institutional experience of 544 consecutive cases.J Am Coll Surg 2005;201:57-65[PMID:15978444 DOI:10.1016/j.jamcollsurg.2005.03.019]
91 Karanicolas PJ,Metrakos P,Chan K,Asmis T,Chen E,Kingham TP,Kemeny N,Porter G,Fields RC,Pingpank J,Dixon E,Wei A,Cleary S,Zogopoulos G,Dey C,D’Angelica M,Fong Y,Dowden S,Ko YJ.Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases:expert consensus statement.Curr Oncol2014;21:e129-e136[PMID:24523610 DOI:10.3747/co.21.1577]
92 Boige V,Malka D,Elias D,Castaing M,De Baere T,Goere D,Dromain C,Pocard M,Ducreux M.Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.Ann Surg Oncol 2008;15:219-226[PMID:17896145 DOI:10.1245/s10434-007-9581-7]
93 Kemeny NE,Niedzwiecki D,Hollis DR,Lenz HJ,Warren RS,Naughton MJ,Weeks JC,Sigurdson ER,Herndon JE,Zhang C,Mayer RJ.Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer:a randomized trial of efficacy,quality of life,and molecular markers(CALGB 9481).JClin Oncol 2006;24:1395-1403[PMID:16505413 DOI:10.1200/JCO.2005.03.8166]
94 Mocellin S,Pilati P,Lise M,Nitti D.Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer:the end of an era?J Clin Oncol 2007;25:5649-5654[PMID:18065736DOI:10.1200/JCO.2007.12.1764]
95 Fiorentini G,Aliberti C,Tilli M,Mulazzani L,Graziano F,Giordani P,Mambrini A,Montagnani F,Alessandroni P,Catalano V,Coschiera P.Intra-arterial infusion of irinotecan-loaded drug-eluting beads(DEBIRI)versus intravenous therapy(FOLFIRI)for hepatic metastases from colorectal cancer:final results of a phase III study.Anticancer Res 2012;32:1387-1395[PMID:22493375]
96 Aliberti C,Tilli M,Benea G,Fiorentini G.Trans-arterial chemoembolization(TACE)of liver metastases from colorectal cancer using irinotecan-eluting beads:preliminary results.Anticancer Res2006;26:3793-3795[PMID:17094403]
97 Fiorentini G,Aliberti C,Turrisi G,Del Conte A,Rossi S,Benea G,Giovanis P.Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads:results of a phase II clinical study.In Vivo 2007;21:1085-1091[PMID:18210761]
98 Aliberti C,Fiorentini G,Muzzio PC,Pomerri F,Tilli M,Dallara S,Benea G.Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead?,drug-eluting bead loaded with irinotecan:results of a phase II clinical study.Anticancer Res2011;31:4581-4587[PMID:22199334]
99 Narayanan G,Barbery K,Suthar R,Guerrero G,Arora G.Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer.Anticancer Res 2013;33:2077-2083[PMID:23645758]
100 Lewis AL,Holden RR.DC Bead embolic drug-eluting bead:clinical application in the locoregional treatment of tumours.Expert Opin Drug Deliv 2011;8:153-169[PMID:21222553 DOI:10.1517/17425247.2011.545388]
101 Fiorentini G,Aliberti C,Mulazzani L,Coschiera P,Catalano V,Rossi D,Giordani P,Ricci S.Chemoembolization in colorectal liver metastases:the rebirth.Anticancer Res 2014;34:575-584[PMID:24510986]
102 Fiorentini G,Aliberti C,Sarti D,Coschiera P,Tilli M,Mulazzani L,Giordani P,Graziano F,Gonzalez AM,Marcos RG,Mugnoz FG,Cantore M,Ricci S,Catalano V,Mambrini A.Locoregional therapy and systemic cetuximab to treat colorectal liver metastases.World J Gastrointest Oncol2015;7:47-54[PMID:26090075 DOI:10.4251/wjgo.v7.i6.47]
103 Aliberti C,Carandina R,Sarti D,Mulazzani L,Catalano V,Felicioli A,Coschiera P,Fiorentini G.Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy.Anticancer Res 2016;36:3515-3521[PMID:27354617]
104 Damm R,Seidensticker R,Ulrich G,Breier L,Steffen IG,Seidensticker M,Garlipp B,Mohnike K,Pech M,Amthauer H,Ricke J.Y90 Radioembolization in chemo-refractory metastastic,liver dominant colorectal cancer patients:outcome assessment applying a predictive scoring system.BMC Cancer 2016;16:509[PMID:27439702 DOI:10.1186/s12885-016-2549-x]
105 Lim L,Gibbs P,Yip D,Shapiro JD,Dowling R,Smith D,Little A,Bailey W,Liechtenstein M.A prospective evaluation of treatment with Selective Internal Radiation Therapy(SIR-spheres)in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.BMC Cancer 2005;5:132[PMID:16225697 DOI:10.1186/1471-2407-5-132]
106 Bester L,Meteling B,Pocock N,Saxena A,Chua TC,Morris DL.Radioembolisation with Yttrium-90 microspheres:an effective treatment modality for unresectable liver metastases.J Med Imaging Radiat Oncol 2013;57:72-80[PMID:23374558 DOI:10.1111/j.1754-9485.2012.02459.x]
107 Cosimelli M,Golfieri R,Cagol PP,Carpanese L,Sciuto R,Maini CL,Mancini R,Sperduti I,Pizzi G,Diodoro MG,Perrone M,Giampalma E,Angelelli B,Fiore F,Lastoria S,Bacchetti S,Gasperini D,Geatti O,Izzo F.Multi-centre phase II clinical trial of yttrium-90resin microspheres alone in unresectable,chemotherapy refractory colorectal liver metastases.Br J Cancer 2010;103:324-331[PMID:20628388 DOI:10.1038/sj.bjc.6605770]
108 Hendlisz A,Van den Eynde M,Peeters M,Maleux G,Lambert B,Vannoote J,De Keukeleire K,Verslype C,Defreyne L,Van Cutsem E,Delatte P,Delaunoit T,Personeni N,Paesmans M,Van Laethem JL,Flamen P.Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.J Clin Oncol 2010;28:3687-3694[PMID:20567019DOI:10.1200/JCO.2010.28.5643]
109 Seidensticker R,Denecke T,Kraus P,Seidensticker M,Mohnike K,Fahlke J,Kettner E,Hildebrandt B,Dudeck O,Pech M,Amthauer H,Ricke J.Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases.Cardiovasc Intervent Radiol 2012;35:1066-1073[PMID:21800231 DOI:10.1007/s00270-011-0234-7]
110 Van Cutsem E,Cervantes A,Adam R,Sobrero A,Van Krieken JH,Aderka D,Aranda Aguilar E,Bardelli A,Benson A,Bodoky G,Ciardiello F,D’Hoore A,Diaz-Rubio E,Douillard JY,Ducreux M,Falcone A,Grothey A,Gruenberger T,Haustermans K,Heinemann V,Hoff P,K?hne CH,Labianca R,Laurent-Puig P,Ma B,Maughan T,Muro K,Normanno N,?sterlund P,Oyen WJ,Papamichael D,Pentheroudakis G,Pfeiffer P,Price TJ,Punt C,Ricke J,Roth A,Salazar R,Scheithauer W,Schmoll HJ,Tabernero J,Ta?eb J,Tejpar S,Wasan H,Yoshino T,Zaanan A,Arnold D.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Ann Oncol 2016;27:1386-1422[PMID:27380959 DOI:10.1093/annonc/mdw235]
111 Lordan JT,Karanjia ND,Quiney N,Fawcett WJ,Worthington TR.A 10-year study of outcome following hepatic resection for colorectal liver metastases-The effect of evaluation in a multidisciplinary team setting.Eur J Surg Oncol 2009;35:302-306[PMID:18328668 DOI:10.1016/j.ejso.2008.01.028]
112 Garden OJ,Rees M,Poston GJ,Mirza D,Saunders M,Ledermann J,Primrose JN,Parks RW.Guidelines for resection of colorectal cancer liver metastases.Gut 2006;55 Suppl 3:iii1-iii8[PMID:16835351DOI:10.1136/gut.2006.098053]
113 Ruiz-Tovar J,López Hervás P.Value of third metastasectomy of colorectal adenocarcinoma.Clin Transl Oncol 2007;9:56-58[PMID:17272232 DOI:10.1007/s12094-007-0011-x]